Expression of inducible nitric oxide synthase in rat experimental autoimmune myocarditis with special reference to changes in cardiac hemodynamics.

Excessive NO produced by an inducible NO synthase (iNOS) has been implicated in many types of immune-associated disorders of the cardiovascular system, but it remains to be determined whether NO plays a role in myocarditis. Thus, the significance of iNOS expression in the development of experimental autoimmune myocarditis (EAM), an animal model of human giant cell myocarditis, was investigated. Lewis rats were immunized with cardiac myosin and were killed 7, 14, 21, 28, and 49 days after immunization. The development of severe myocarditis was observed on days 14, 21, and 28 in association with significant deterioration of hemodynamics determined by cardiac catheterization, which peaked on day 21. In parallel with histological severity of myocarditis and deterioration of cardiac performance, iNOS activity in the heart measured by [14C]L-citrulline formation was markedly increased on days 14, 21, and 28. The expression of iNOS was confirmed by immunoblotting and was localized to the infiltrating inflammatory cells found in the vicinity of necrotic myocytes by immunohistochemical analysis. Aminoguanidine, a selective inhibitor of iNOS, significantly decreased the iNOS activity (1.04 +/- 0.37 compared with 29.1 +/- 8.62 pmol.min-1.mg protein-1 in untreated myosin-immunized rats, P < .01) and effectively attenuated histopathological changes of EAM on day 21. Hemodynamic parameters were also improved from 64 +/- 3 to 89 +/- 3 mm Hg for mean blood pressure, from 80 +/- 2 to 113 +/- 4 mm Hg for left ventricular systolic pressure, from 7.8 +/- 0.3 to 3.2 +/- 0.3 mm Hg for left ventricular end-diastolic pressure, from 2867 +/- 137 to 4180 +/- 102 mm Hg/s for +dP/dt, and from 2717 +/- 132 to 4180 +/- 184 mm Hg/s for -dP/dt (P < .01). The values after aminoguanidine treatment were not significantly different from the control values. These results suggest an important role for NO in mediating pathophysiological changes in myocarditis of autoimmune origin.

[1]  Erin G. Brooks.  Giant Cell Myocarditis , 2020, Definitions.

[2]  J. Williamson,et al.  Inhibition of inducible nitric oxide synthase prevents myocardial and systemic vascular barrier dysfunction during early cardiac allograft rejection. , 1996, Circulation research.

[3]  B. McManus,et al.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. , 1995, The New England journal of medicine.

[4]  F. Marumo,et al.  Vasopressin increases AQP-CD water channel in apical membrane of collecting duct cells in Brattleboro rats. , 1995, The American journal of physiology.

[5]  M. Kodama,et al.  Effects of 15-deoxyspergualin on experimental autoimmune giant cell myocarditis of the rat. , 1995, Circulation.

[6]  F. László,et al.  Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo. , 1995, European journal of pharmacology.

[7]  T. P. Misko,et al.  Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase , 1995, The Journal of experimental medicine.

[8]  M. Grisham,et al.  Effects of nitric oxide synthase inhibition on the pathophysiology observed in a model of chronic granulomatous colitis. , 1994, The Journal of pharmacology and experimental therapeutics.

[9]  P. Macdonald,et al.  Increased nitric oxide production in heart failure , 1994, The Lancet.

[10]  C. Marboe,et al.  Induction of myocardial nitric oxide synthase by cardiac allograft rejection. , 1994, The Journal of clinical investigation.

[11]  A. Cross,et al.  Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. , 1994, The Journal of clinical investigation.

[12]  W. Barry.  Mechanisms of immune-mediated myocyte injury. , 1994, Circulation.

[13]  G. Schreiner,et al.  Immune mechanisms of cardiac disease. , 1994, The New England journal of medicine.

[14]  S. Moncada,et al.  The L-arginine-nitric oxide pathway. , 1993, The New England journal of medicine.

[15]  T. Evans,et al.  Aminoguanidine selectively inhibits inducible nitric oxide synthase , 1993, British journal of pharmacology.

[16]  E. Unanue,et al.  Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine-sensitive and -resistant stages in the immunological diabetic process. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Rennard,et al.  Inhibitors of nitric oxide synthase attenuate human neutrophil chemotaxis in vitro. , 1993, The Journal of laboratory and clinical medicine.

[18]  S. Wahl,et al.  Suppression of arthritis by an inhibitor of nitric oxide synthase , 1993, The Journal of experimental medicine.

[19]  R. Robbins,et al.  Nitric oxide synthase inhibitors attenuate human monocyte chemotaxis in vitro , 1993, Journal of leukocyte biology.

[20]  A. Shah,et al.  Modulation of myocardial contraction by endocardial and coronary vascular endothelium. , 1993, Trends in cardiovascular medicine.

[21]  M. Mcdaniel,et al.  Selective inhibition of inducible nitric oxide synthase by aminoguanidine. , 1993, Methods in enzymology.

[22]  S. Moncada,et al.  Nitric oxide synthase activities in human myocardium , 1993, The Lancet.

[23]  J. Stamler,et al.  Biochemistry of nitric oxide and its redox-activated forms. , 1992, Science.

[24]  P. Winocour.  Platelet Abnormalities in Diabetes Mellitus , 1992, Diabetes.

[25]  J. Witztum,et al.  Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Kodama,et al.  In Vivo Lymphocyte‐Mediated Myocardial Injuries Demonstrated by Adoptive Transfer of Experimental Autoimmune Myocarditis , 1992, Circulation.

[27]  M. Mcdaniel,et al.  Aminoguanidine, a Novel Inhibitor of Nitric Oxide Formation, Prevents Diabetic Vascular Dysfunction , 1992, Diabetes.

[28]  M. Kodama,et al.  An immunosuppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats. , 1992, Clinical immunology and immunopathology.

[29]  S. Moncada,et al.  Induction and potential biological relevance of a Ca2+‐independent nitric oxide synthase in the myocardium , 1992, British journal of pharmacology.

[30]  S. Moncada,et al.  Modulation of acute inflammation by endogenous nitric oxide. , 1992, European journal of pharmacology.

[31]  M. Brownlee,et al.  Mechanistic Studies of Advanced Glycosylation End Product Inhibition by Aminoguanidine , 1992, Diabetes.

[32]  P. Vallance,et al.  Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock , 1991, The Lancet.

[33]  S. Imai,et al.  Cyclic GMP-dependent protein kinase stimulates the plasma membrane Ca2+ pump ATPase of vascular smooth muscle via phosphorylation of a 240-kDa protein. , 1991, The Journal of biological chemistry.

[34]  M. Kodama,et al.  Characteristics of giant cells and factors related to the formation of giant cells in myocarditis. , 1991, Circulation research.

[35]  P. Kubes,et al.  Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. K. Sahib,et al.  Monoaminoguanidine inhibits aldose reductase. , 1991, Biochemical pharmacology.

[37]  J. Fallon,et al.  Giant Cell Versus Lymphocytic Myocarditis: A Comparison of Their Clinical Features and Long‐term Outcomes , 1991, Circulation.

[38]  R Fischmeister,et al.  Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Brain,et al.  Evidence that endogenous nitric oxide modulates oedema formation induced by substance P. , 1990, European journal of pharmacology.

[40]  M. Kodama,et al.  A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. , 1990, Clinical immunology and immunopathology.

[41]  M. Salter,et al.  Differential induction of brain, lung and liver nitric oxide synthase by endotoxin in the rat. , 1990, The Biochemical journal.

[42]  T. Billiar,et al.  Inhibition of chemotaxis Ng-monomethyl-L-arginine: a role for cyclic GMP. , 1989, Blood.

[43]  C. Nathan,et al.  Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells , 1989, The Journal of experimental medicine.

[44]  J. Drapier,et al.  Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. , 1988, Journal of Immunology.

[45]  J. Drapier,et al.  Murine cytotoxic activated macrophages inhibit aconitase in tumor cells. Inhibition involves the iron-sulfur prosthetic group and is reversible. , 1986, The Journal of clinical investigation.

[46]  A. Lerner,et al.  Coxsackievirus myocarditis--with special reference to acute and chronic effects. , 1985, Progress in cardiovascular diseases.

[47]  R. A. Johnson,et al.  Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. , 1985, The New England journal of medicine.

[48]  J. McGee,et al.  Giant cell myocarditis: evidence for the macrophage origin of the giant cells. , 1985, Journal of clinical pathology.

[49]  W. Lorenz,et al.  Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism. , 1983, Biochimica et biophysica acta.

[50]  M. Hess,et al.  Left Ventricular Mass By M‐mode Echocardiography in Cardiac Transplant Patients with Acute Rejection , 1981, Circulation.

[51]  G. Peterson,et al.  A simplification of the protein assay method of Lowry et al. which is more generally applicable. , 1977, Analytical biochemistry.

[52]  H. R. Besch,et al.  Interaction between Cyclic Adenosine Monophosphate and Cyclic Guanosine Monophosphate in Guinea Pig Ventricular Myocardium , 1975, Circulation research.

[53]  M. Kodama,et al.  Giant Cell Myocarditis , 2005 .

[54]  J. Balligand,et al.  Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[55]  H. Kolb,et al.  Nitric oxide: a pathogenetic factor in autoimmunity. , 1992, Immunology today.

[56]  N. Seiler,et al.  The influence of catabolic reactions on polyamine excretion. , 1985, The Biochemical journal.